Bridging the Conjugation Gap: Maintaining Disulfide Bridges Leads to Improved Homogeneity and Stability for ADCs


Antony Godwin. Genetic Engineering & Biotechnology News. January 2013, 33(3): 20-21. doi:10.1089/gen.33.3.10.

A new wave of antibody-target anticancer therapies is showing great clinical promise, with the potential to transform cancer treatment. These antibody-durg conjugates (ADCs) are multicomponent systems that combine recombinant and chemical technologies to deliver a highly potent cytotoxic drug to a tumor thereby monimizing off target toxicities and increasing the therapeutic window of the drug. …

Read the full article here

Interested in our services? Get In Touch